health

Lilly rides Mounjaro, Zepbound to better

Font size+Author:World Whirl news portalSource:world2024-05-21 22:11:13I want to comment(0)

Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro,

Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.

The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.

Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.

They expect significant manufacturing increases to occur, starting in the back half of the year.

CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”

Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.

Related articles
  • Analysis: Larson enters conversation with Verstappen as best drivers in the world

    Analysis: Larson enters conversation with Verstappen as best drivers in the world

    2024-05-21 21:44

  • Is taking a Nile river cruise in Egypt worth it? I filmed my five

    Is taking a Nile river cruise in Egypt worth it? I filmed my five

    2024-05-21 21:23

  • A nation of explorers? Poll reveals that nearly a quarter of Brits have never even visited SCOTLAND

    A nation of explorers? Poll reveals that nearly a quarter of Brits have never even visited SCOTLAND

    2024-05-21 21:09

  • Exquisite suites and unrivalled experiences

    Exquisite suites and unrivalled experiences

    2024-05-21 20:55

Netizen comments